Geoffrey Dolan
Rheumatology · Long Beach, CANPI 1811910847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 530 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Amgen at 29.5% of the total.
Across 530 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- Johnson & Johnson$788
- Lilly USA, LLC$643
- Novartis$577
- Pfizer$442
- plus $2K from 22 others
Across 1 payment — averaging $2132.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2K
What the payments were for
- Food & beverage$9,510100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 146 | $2,804 |
| AbbVie | 125 | $2,224 |
| Johnson & Johnson(3 entities) | 46 | $788 |
| Lilly USA, LLC | 35 | $643 |
| Novartis | 42 | $577 |
| Pfizer | 34 | $442 |
| Boehringer Ingelheim | 12 | $318 |
| Bristol Myers Squibb | 14 | $267 |
| Amarin Pharma, Inc. | 13 | $237 |
| GSK | 11 | $225 |
| E.r. Squibb & Sons, L.L.C. | 8 | $166 |
| Sanofi | 9 | $157 |
| Radius Health, Inc. | 6 | $142 |
| AstraZeneca(2 entities) | 6 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $59 |
| UCB, Inc. | 2 | $52 |
| Merck | 3 | $41 |
| Genentech USA, Inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Antares Pharma, Inc. | 2 | $29 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Medexus Pharma, Inc. | 1 | $21 |
| Bioventus LLC | 1 | $21 |
| Fidia Pharma USA Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,514 in reported general payments places this provider in the 70th percentile of 808 rheumatology providers in California.
Other rheumatology in Long Beach
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.